Press releases
Latest press releases and new announcements from Adcendo
Press materials
Adcendo ApS to Present Data on its Novel ADC Target uPARAP in Glioblastoma Multiforme at the American Association for Cancer Research Annual Meeting 2024
Data demonstrate that uPARAP is highly expressed in tumor samples obtained from glioblastoma multiforme patients uPARAP targeting ADC shows cytotoxicity in glioblastoma multiforme cancer cells in vitro and exhibits potent in vivo anti-tumor activity in a glioblastoma...
Adcendo Appoints Experienced Drug Developer Dr. Lone H. Ottesen as Chief Medical Officer
Dr. Ottesen brings in-depth global clinical development expertise in oncology, including biologics, small molecules, immunotherapies and ADCs Adcendo further builds its world class team to accelerate development of lead ADC asset uPARAP and to expand its...
Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand First-in-class ADC Pipeline
Strengthening of strategic option license agreement to cover additional novel ADC targets Copenhagen, Denmark, May 30th, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of...
Adcendo ApS to Present Data on the Expression of the Novel ADC target uPARAP in Soft Tissue and Bone Sarcoma at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Data demonstrate that uPARAP is widely expressed at high levels across multiple sarcoma subtypes Strong overexpression in tumors combined with low expression levels in normal human tissues makes uPARAP an attractive candidate for therapeutic targeting of sarcomas by...
Adcendo ApS Announces Extension of Series A financing to 82M EUR to Ensure Broad Development of its First-in-class ADC Pipeline
Series A Financing extension led by Pontifax Venture Capital and existing investors Novo Holdings and Ysios Capital, raising an additional 31M EUR Funds will be used to ensure broad pan-sarcoma development of lead ADC assetuPARAP and to further advance second ADC...
Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform
Adcendo licenses Duality’s DITAC (Duality Immune Toxin Antibody Conjugates) linker/payload platform for its lead uPARAP-ADC program Agreement based on synergies between Adcendo and Duality in generating breakthrough ADCs in hard-to-treat cancers Copenhagen, Denmark,...
GlyTherix and Adcendo Announce Agreement for Development of Antibody Drug Conjugate
GlyTherix Ltd (“GlyTherix”), an Australian immune-oncology company today announced an MTA & Option License with Adcendo ApS (“Adcendo”), a Danish biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of...
Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer
Brings in-depth R&D expertise in oncology, including ADCs, targeted radiotherapies, immunooncology and small molecules
Adcendo building a world class team of experienced biotech & pharma executives and renowned leaders in the ADC field
Data Presentation on uPARAP targeting ADCs in Osteosarcoma PDX Models at the 2022 AACR Annual Meeting
The poster presentation highlights the preclinical evaluation of several of Adcendo´s ADC candidates for the treatment of osteosarcoma
Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders
Building the team with experienced biotech experts and renowned leaders in the ADC field and
Underscores company’s commitment to progressing lead program on novel ADC target uPARAP